Access to innovative therapies in pediatric oncology: Report of the nationwide experience in Canada.
immunotherapy
precision oncology
real-world data
targeted therapy
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
Feb 2024
Feb 2024
Historique:
revised:
31
01
2024
received:
13
11
2023
accepted:
08
02
2024
medline:
24
2
2024
pubmed:
24
2
2024
entrez:
24
2
2024
Statut:
ppublish
Résumé
The need for new therapies to improve survival and outcomes in pediatric oncology along with the lack of approval and accessible clinical trials has led to "out-of-trial" use of innovative therapies. We conducted a retrospective analysis of requests for innovative anticancer therapy in Canadian pediatric oncology tertiary centers for patients less than 30 years old between 2013 and 2020. Innovative therapies were defined as cancer-directed drugs used (a) off-label, (b) unlicensed drugs being used outside the context of a clinical trial, or (c) approved drugs with limited evidence in pediatrics. We excluded cytotoxic chemotherapy, cellular products, and cytokines. We retrieved data on 352 innovative therapy drug requests. Underlying diagnosis was primary CNS tumor 31%; extracranial solid tumor 37%, leukemia/lymphoma 22%, LCH 2%, and plexiform neurofibroma 6%. RAS/MAP kinase pathway inhibitors were the most frequently requested innovative therapies in 28% of all requests followed by multi-targeted tyrosine kinase inhibitors (17%), inhibitors of the PIK3CA-mTOR-AKT pathway (8%), immune checkpoints inhibitors (8%), and antibody drug conjugates (8%). In 112 out of 352 requests, innovative therapies were used in combination with another anticancer agent. 48% of requests were motivated by the presence of an actionable molecular target. Compassionate access accounted for 52% of all requests while public insurance was used in 27%. Mechanisms of funding varied between provinces. This real-world data collection illustrates an increasing use of "out-of-trial" innovative therapies in pediatric oncology. This new field of practice warrants further studies to understand the impact on patient trajectory and equity in access to innovative therapies.
Sections du résumé
BACKGROUND
BACKGROUND
The need for new therapies to improve survival and outcomes in pediatric oncology along with the lack of approval and accessible clinical trials has led to "out-of-trial" use of innovative therapies. We conducted a retrospective analysis of requests for innovative anticancer therapy in Canadian pediatric oncology tertiary centers for patients less than 30 years old between 2013 and 2020.
METHODS
METHODS
Innovative therapies were defined as cancer-directed drugs used (a) off-label, (b) unlicensed drugs being used outside the context of a clinical trial, or (c) approved drugs with limited evidence in pediatrics. We excluded cytotoxic chemotherapy, cellular products, and cytokines.
RESULTS
RESULTS
We retrieved data on 352 innovative therapy drug requests. Underlying diagnosis was primary CNS tumor 31%; extracranial solid tumor 37%, leukemia/lymphoma 22%, LCH 2%, and plexiform neurofibroma 6%. RAS/MAP kinase pathway inhibitors were the most frequently requested innovative therapies in 28% of all requests followed by multi-targeted tyrosine kinase inhibitors (17%), inhibitors of the PIK3CA-mTOR-AKT pathway (8%), immune checkpoints inhibitors (8%), and antibody drug conjugates (8%). In 112 out of 352 requests, innovative therapies were used in combination with another anticancer agent. 48% of requests were motivated by the presence of an actionable molecular target. Compassionate access accounted for 52% of all requests while public insurance was used in 27%. Mechanisms of funding varied between provinces.
CONCLUSION
CONCLUSIONS
This real-world data collection illustrates an increasing use of "out-of-trial" innovative therapies in pediatric oncology. This new field of practice warrants further studies to understand the impact on patient trajectory and equity in access to innovative therapies.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e7033Informations de copyright
© 2024 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
The global burden of childhood and adolescent cancer in 2017: an analysis of the global burden of disease study 2017. Lancet Oncol. 2019;20(9):1211-1225. doi:10.1016/S1470-2045(19)30339-0
Yeh JM, Ward ZJ, Chaudhry A, et al. Life expectancy of adult survivors of childhood cancer over 3 decades. JAMA Oncol. 2020;6(3):350-357. doi:10.1001/jamaoncol.2019.5582
Williams AM, Liu Q, Bhakta N, et al. Rethinking success in pediatric oncology: beyond 5-year survival. J Clin Oncol. 2021;39(20):2227-2231. doi:10.1200/JCO.20.03681
Bird N, Knox L, Palmer A, et al. When innovation and commercialization collide: a patient advocate view in neuroblastoma. J Clin Oncol. 2022;40(2):120-126. doi:10.1200/JCO.21.01916
Neel DV, Shulman DS, DuBois SG. Timing of first-in-child trials of FDA-approved oncology drugs. Eur J Cancer. 2019;112:49-56. doi:10.1016/j.ejca.2019.02.011
Denburg AE, Ungar WJ, Greenberg M. Public drug policy for children in Canada. CMAJ. 2017;189(30):E990-E994. doi:10.1503/cmaj.170380
Bouffet E, Geoerger B, Moertel C, et al. Efficacy and safety of trametinib monotherapy or in combination with dabrafenib in pediatric BRAF V600-mutant low-grade glioma. J Clin Oncol. 2023;41(3):664-674. doi:10.1200/JCO.22.01000
Davis LE, Bolejack V, Ryan CW, et al. Randomized double-blind phase II study of regorafenib in patients with metastatic osteosarcoma. J Clin Oncol. 2019;37(16):1424-1431. doi:10.1200/JCO.18.02374
Cohen-Gogo S, Denburg AE, Villani A, et al. Precision oncology for children: a primer for paediatricians. Paediatr Child Health. 2023;28:278-284. doi:10.1093/pch/pxac123
Blauel ER, Laetsch TW. The promise of TRK inhibitors in pediatric cancers with NTRK fusions. Cancer Genet. 2022;262-263:71-79. doi:10.1016/j.cancergen.2022.01.004
Revon-Riviere G, Young LC, Stephenson EA, et al. Ensuring access to innovative therapies for children, adolescents, and young adults across Canada: the single patient study experience. Paediatr Child Health. 2023;28:399-403. doi:10.1093/pch/pxac122
Pearson ADJ, Weiner SL, Adamson PC, et al. ACCELERATE-five years accelerating cancer drug development for children and adolescents. Eur J Cancer. 2022;166:145-164. doi:10.1016/j.ejca.2022.01.033
Lim M, Shulman DS, Roberts H, et al. Off-label prescribing of targeted anticancer therapy at a large pediatric cancer center. Cancer Med. 2020;9(18):6658-6666. doi:10.1002/cam4.3349
Shulman DS, Kiwinda LV, Edwards S, et al. Retrospective evaluation of single patient investigational new drug (IND) requests in pediatric oncology. Cancer Med. 2021;10(7):2310-2318. doi:10.1002/cam4.3791
Sabnis HS, Shulman DS, Mizukawa B, et al. Multicenter analysis of Genomically targeted single patient use requests for pediatric neoplasms. J Clin Oncol. 2021;39(34):3822-3828. doi:10.1200/JCO.21.01213
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377-381. doi:10.1016/j.jbi.2008.08.010
Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208. doi:10.1016/j.jbi.2019.103208
Saiyed MM, Ong PS, Chew L. Off-label drug use in oncology: a systematic review of literature. J Clin Pharm Ther. 2017;42(3):251-258. doi:10.1111/jcpt.12507
Vashistha V, Katsoulakis E, Guo A, Price M, Ahmed S, Kelley MJ. Molecular-guided off-label targeted therapy in a large-scale precision oncology program. JCO Precis Oncol. 2023;7:e2200518. doi:10.1200/PO.22.00518
Berlanga P, Ndounga-Diakou LA, Aerts I, et al. Measuring safety and outcomes for the use of compassionate and off-label therapies for children, adolescents, and Young adults with cancer in the SACHA-France study. JAMA Netw Open. 2023;6(7):e2321568. doi:10.1001/jamanetworkopen.2023.21568
Coltin H, Perreault S, Larouche V, et al. Selumetinib for symptomatic, inoperable plexiform neurofibromas in children with neurofibromatosis type 1: a national real-world case series. Pediatr Blood Cancer. 2022;69(8):e29633. doi:10.1002/pbc.29633
van Tilburg CM, Pfaff E, Pajtler KW, et al. The pediatric precision oncology INFORM registry: clinical outcome and benefit for patients with very high-evidence targets. Cancer Discov. 2021;11(11):2764-2779. doi:10.1158/2159-8290.CD-21-0094
Berlanga P, Pierron G, Lacroix L, et al. The European MAPPYACTS trial: precision medicine program in pediatric and adolescent patients with recurrent malignancies. Cancer Discov. 2022;12(5):1266-1281. doi:10.1158/2159-8290.CD-21-1136
Gaspar N, Marshall LV, Binner D, et al. Joint adolescent-adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platform-ACCELERATE. Ann Oncol. 2018;29(3):766-771. doi:10.1093/annonc/mdy002
Gore L, Ivy SP, Balis FM, et al. Modernizing clinical trial eligibility: recommendations of the American Society of Clinical Oncology-friends of cancer research minimum age working group. J Clin Oncol. 2017;35(33):3781-3787. doi:10.1200/JCO.2017.74.4144
Sundquist S, Batist G, Brodeur-Robb K, et al. CRAFT-A proposed framework for decentralized clinical trials participation in Canada. Curr Oncol. 2021;28(5):3857-3865. doi:10.3390/curroncol28050329
Moerdler S, Zhang L, Gerasimov E, et al. Physician perspectives on compassionate use in pediatric oncology. Pediatr Blood Cancer. 2019;66(3):e27545. doi:10.1002/pbc.27545